Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Shuttle Pharmaceuticals (SHPH)

Shuttle Pharmaceuticals Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SHPH
DateTimeSourceHeadlineSymbolCompany
18/06/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
18/06/202414:00GlobeNewswire Inc.Shuttle Pharma Appoints Timothy Lorber as Chief Financial OfficerNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/06/202411:12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/05/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/05/202421:15GlobeNewswire Inc.Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/05/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/05/202414:00GlobeNewswire Inc.Shuttle Pharma Provides First Quarter 2024 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/05/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/04/202421:15GlobeNewswire Inc.Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/03/202413:00PR Newswire (US)Shuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/03/202423:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
05/03/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/02/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/02/202413:00PR Newswire (US)Shuttle Pharma Announces Its Intent to Pursue a Rights OfferingNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
05/02/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/01/202421:30PR Newswire (US)Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/01/202414:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/01/202414:00PR Newswire (US)Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
02/01/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
21/12/202302:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
19/12/202322:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/12/202314:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/12/202314:00PR Newswire (US)Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
30/11/202314:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/11/202314:00PR Newswire (US)Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/11/202321:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
31/10/202313:00PR Newswire (US)Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
30/10/202321:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202321:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202321:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SHPH